Fibrosing mediastinitis is a rare disease characterized by fibrosis of mediastinal structures with subsequent constriction of the bronchi and pulmonary vessels leading to potential respiratory compromise and death. Presently, there is no effective curative treatment with available treatments focused on reducing symptomology, including placement of pulmonary artery stents. Limited studies examine the use of stents in fibrosing mediastinitis. Given this knowledge gap, we assessed stent patency, hemodynamics, complications, and secondary outcomes of clinical improvement of pulmonary artery stenting for fibrosing mediastinitis.
Materials and Methods
Nine patients with fibrosing mediastinitis and pulmonary artery stents were retrospectively identified for inclusion (six females, three males; mean age 44.17 years, range 13–68; total 13 primary stents) from 2005 to 2018. Eight patients had history of PH. All patients had dyspnea on presentation. Seven patients had ventilation/perfusion studies demonstrating impairment. Results from computed tomography and echocardiography studies were collected to assess patency and physiologic response.
All patients received initial angioplasty and stenting of the right pulmonary artery (10 stents). Two patients underwent additional left-sided intervention (3 stents). Stenting significantly increased lesion luminal patency (54–79%; P < 0.005) and reduced systolic pressure gradients across stenoses (mean −9.38 mmHg; P < 0.005). Primary patency at one year was 90%. Two stents received reintervention at 276 and 497 days. 89% reported improvement in dyspnea in the initial post-stenting period. There were no mortalities or major complications.
Pulmonary artery stenting improves vascular patency and provides symptomatic relief in patients with fibrosing mediastinitis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20(1):115–32. https://doi.org/10.1128/cmr.00027-06.
Schowengerdt CG, Suyemoto R, Main FB. Granulomatous and fibrous mediastinitis: a review and analysis of 180 cases. J Thorac Cardiovas Surg. 1969;57(3):365–79.
Berry DF, Buccigrossi D, Peabody J, Peterson KL, Moser KM. Pulmonary vascular occlusion and fibrosing mediastinitis. Chest. 1986;89(2):296–301.
Peikert T, Colby TV, Midthun DE, Pairolero PC, Edell ES, Schroeder DR, et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore). 2011;90(6):412–23. https://doi.org/10.1097/MD.0b013e318237c8e6.
Loyd JE, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore). 1988;67(5):295–310. https://doi.org/10.1097/00005792-198809000-00002.
Mathisen DJ, Grillo HC. Clinical manifestation of mediastinal fibrosis and histoplasmosis. Ann Thorac Surg. 1992;54(6):1053–8.
Brown ML, Cedeno AR, Edell ES, Hagler DJ, Schaff HV. Operative strategies for pulmonary artery occlusion secondary to mediastinal fibrosis. Ann Thorac Surg. 2009;88(1):233–7. https://doi.org/10.1016/j.athoracsur.2009.04.012.
Fender EA, Widmer RJ, Knavel Koepsel EM, Welby JP, Kern R, Peikert T, et al. Catheter based treatments for fibrosing mediastinitis. Catheter Cardiovasc Interv Off J Soc Cardiac Angiogr Interv. 2019. https://doi.org/10.1002/ccd.28152.
Fogelman R, Nykanen D, Smallhorn JF, McCrindle BW, Freedom RM, Benson LN. Endovascular stents in the pulmonary circulation: clinical impact on management and medium-term follow-up. Circulation. 1995;92(4):881–5.
Lewis MJ, Kennedy KF, Ginns J, Crystal MA, Torres A, Vincent J, et al. Procedural success and adverse events in pulmonary artery stenting: insights from the NCDR. J Am Coll Cardiol. 2016;67(11):1327–35. https://doi.org/10.1016/j.jacc.2016.01.025.
Kenny D, Amin Z, Slyder S, Hijazi ZM. Medium-term outcomes for peripheral pulmonary artery stenting in adults with congenital heart disease. J Interv Cardiol. 2011;24(4):373–7.
Seferian A, Steriade A, Jaïs X, Planché O, Savale L, Parent F, et al. PH complicating fibrosing mediastinitis. Medicine. 2015;94(44):e1800.
Doyle TP, Loyd JE, Robbins IM. Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am J Respir Crit Care Med. 2001;164(4):657–60. https://doi.org/10.1164/ajrccm.164.4.2012132.
Guerrero A, Karmy-Jones R, Hoffer EK, Hudson L, Schuler P. Treatment of pulmonary artery compression due to fibrous mediastinitis with endovascular stent placement. Chest. 2001;119(3):966–8. https://doi.org/10.1378/chest.119.3.966.
Kandzari DE, Warner JJ, O’Laughlin MP, Harrison JK. Percutaneous stenting of right pulmonary artery stenosis in fibrosing mediastinitis. Catheter Cardiovasc Interv. 2000;49(3):321–4.
Fontaine AB, Borsa JJ, Hoffer EK, Bloch RD, So C. Stent placement in the treatment of pulmonary artery stenosis secondary to fibrosing mediastinitis. J Vasc Interv Radiol. 2001;12(9):1107–11. https://doi.org/10.1016/S1051-0443(07)61600-5.
Argueta F, Villafuerte D, Castaneda-Nerio J, Peters J, Restrepo C. Successful management of fibrosing mediastinitis with severe vascular compromise: Report of two cases and literature review. Respir Med Case Rep. 2020;29:100987.
Satpathy R, Aguila V, Mohiuddin SM, Khan IA. Fibrosing mediastinitis presenting as pulmonary stenosis: stenting works. Int J Cardiol. 2007;118(3):e85–6.
Thiessen R, Matzinger F, Seely J, Aina R, MacLeod P. Fibrosing mediastinitis: successful stenting of the pulmonary artery. Canadian respiratory journal. 2008;15:41–4.
Ferguson ME, Cabalka AK, Cetta F, Hagler DJ. Results of intravascular stent placement for fibrosing mediastinitis. Congenit Heart Dis. 2010;5(2):124–33. https://doi.org/10.1111/j.1747-0803.2010.00387.x.
Smith JS, Kadiev S, Diaz P, Cheatham J. Pulmonary artery stenosis secondary to fibrosing mediastinitis: management with cutting balloon angioplasty and endovascular stenting. Vasc Endovasc Surg. 2011;45(2):170–3.
Hamilton-Craig C, Slaughter R, McNeil K, Kermeen F, Walters D. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ. 2009;18(3):222–5.
Albers EL, Pugh ME, Hill KD, Wang L, Loyd JE, Doyle TP. Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis. Circulation. 2011;123(13):1391–9. https://doi.org/10.1161/circulationaha.110.949180.
Crystal MA, Ing FF. Pulmonary artery stents: past, present and future. Prog Pediatr Cardiol. 2012;33(2):151–9.
Zablah JE, Morgan GJ. Pulmonary artery stenting. Interv Cardiol Clin. 2019;8(1):33–46.
Hallbergson A, Lock JE, Marshall AC. Frequency and risk of in-stent stenosis following pulmonary artery stenting. Am J Cardiol. 2014;113(3):541–5.
Khalilzadeh O, Baerlocher MO, Shyn PB, Connolly BL, Devane AM, Morris CS, et al. Proposal of a new adverse event classification by the society of interventional radiology standards of practice committee. J Vasc Interv Radiol. 2017;28(10):1432.e3-7.e3.
Sherrick AD, Brown LR, Harms GF, Myers JL. The radiographic findings of fibrosing mediastinitis. Chest. 1994;106(2):484–9.
Davis AM, Pierson RN, Loyd JE. Mediastinal fibrosis. Seminars in respiratory infections. 2001;16:119–30.
Westerly BD, Johnson GB, Maldonado F, Utz JP, Specks U, Peikert T. Targeting B lymphocytes in progressive fibrosing mediastinitis. Am J Respir Crit Care Med. 2014;190(9):1069–71.
Rossi SE, McAdams HP, Rosado-de-Christenson ML, Franks TJ, Galvin JR. Fibrosing mediastinitis. RadioGraphics. 2001;21(3):737–57. https://doi.org/10.1148/radiographics.21.3.g01ma17737.
McNeeley MF, Chung JH, Bhalla S, Godwin JD. Imaging of granulomatous fibrosing mediastinitis. Am J Roentgenol. 2012;199(2):319–27.
Holzer RJ, Gauvreau K, Kreutzer J, Leahy R, Murphy J, Lock JE, et al. Balloon angioplasty and stenting of branch pulmonary arteries: adverse events and procedural characteristics: results of a multi-institutional registry. Circ Cardiovasc Interv. 2011;4(3):287–96.
This study was not supported by any funding.
Conflict of interest
The authors declare that they have no conflict of interested.
For this type of study, formal consent is not required. Institutional Review Board (IRB) approval was obtained.
This study obtained IRB approval, and the need for informed consent was waived.
Consent for Publication
Consent for publication was obtained for every individual person’s data included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Welby, J.P., Fender, E.A., Peikert, T. et al. Evaluation of Outcomes Following Pulmonary Artery Stenting in Fibrosing Mediastinitis. Cardiovasc Intervent Radiol 44, 384–391 (2021). https://doi.org/10.1007/s00270-020-02714-z
- Pulmonary artery stent
- Fibrosing mediastinitis